1-(2-氨基-5-吡咯烷-1-基苯基)乙酮 | 56915-84-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-氨基-5-吡咯烷-1-基苯基)乙酮
• 英文名称: (2'-amino-5'-pyrrolidinyl)acetophenone
• 英文别名: 2-amino-5-pyrroloacetophenone；2'-amino-5'-(1-pyrrolidinyl)-acetophenone；5-Pyrrolidino-2-aminoacetophenone；1-[2-Amino-5-(1-pyrrolidinyl)phenyl]-1-ethanone；1-(2-amino-5-pyrrolidin-1-ylphenyl)ethanone
• CAS: 56915-84-5
• 化学式: C₁₂H₁₆N₂O
• 分子量: 204.272
• InChiKey: LAXMYAGCDPTAGX-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81°C

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(2-氨基-5-吡咯烷-1-基苯基)乙酮 在 sodium hydroxide 作用下， 以 二苯醚 、 乙醇 为溶剂， 反应 1.0h， 生成 2-(3-Methoxy-phenyl)-6-pyrrolidin-1-yl-2,3-dihydro-1H-quinolin-4-one
  参考文献：
  名称：

  抗肿瘤药。181.6,7,2'，3'，4'-取代的1,2,3,4,4-四氢-2-苯基-4-喹诺酮类作为一类新型抗有丝分裂抗肿瘤剂的合成及生物学评价。

  摘要：

  合成了一系列新的6,7,2'，3'，4'-取代的1,2,3,4-四氢-2-苯基-4-喹诺酮类化合物，并评估了其与微管蛋白的相互作用以及对A的细胞毒活性。人类肿瘤细胞系，包括回盲肠癌（HCT-8），乳腺癌（MCF-7），肺癌（A-549），鼻咽表皮样癌（KB），肾癌（CAKI-1）和黑色素瘤癌症（SKMEL-2）。大多数化合物（18、20、22-27）显示出有效的细胞毒性和抗微管蛋白作用。活性最高的化合物（23、26、27）在几乎所有肿瘤细胞系中均表现出很强的细胞毒性作用，其ED50值在纳摩尔或亚纳摩尔范围内。将三个活性外消旋物（20、22、25）分离为对映异构体，通常，将光学纯的（-）-异构体（20a，22a，25a）显示出比外消旋物或（+）-异构体更大的生物活性。细胞毒性和抗微管蛋白活性密切相关，活性最高的化合物（23、26、27）具有与秋水仙碱，鬼臼毒素和康维他汀A-4相当的作用。

  DOI：

  10.1021/jm9707479
• 作为产物：
  描述：

  3-氯苯乙酮 在 palladium on activated charcoal 硫酸 、 氢气 、 硝酸 作用下， 生成 1-(2-氨基-5-吡咯烷-1-基苯基)乙酮
  参考文献：
  名称：

  Antitumor Agents 155. Synthesis and Biological Evaluation of 3',6,7-Substituted 2-Phenyl-4-quinolones as Antimicrotubule Agents

  摘要：

  A series of 3',6,7-substituted 2-phenyl-4-quinolones were designed and synthesized as antimitotic antitumor agents. All compounds showed cytotoxic effects (log GI(50) less than or equal to -4.0; log drug molar concentration required to cause 50% inhibition) against the growth of a variety of human tumor cell lines, including those derived from solid tumors such as non-small cell lung, colon, central nervous system, ovary, prostate, and breast cancers, when evaluated in the National Cancer Institute's 60 human tumor cell line in vitro screen. The most potent compound (26) demonstrated strong cytotoxic effects with GI(50) values in the nanomolar or subnanomolar range in almost all the tumor cell lines. Compound 26 was also a potent inhibitor of tubulin polymerization and radiolabeled colchicine binding to tubulin, with activity comparable to those of the potent antimitotic natural products colchicine, podophyllotoxin, and combretastatin A-4.

  DOI：

  10.1021/jm00046a025

文献信息

• SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES
  申请人：Kuo Sheng-Chu

  公开号：US20120015908A1

  公开（公告）日：2012-01-19

  A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH) 2 , P(═O)(O(C 1 -C 18 )alkylene(C 6 -C 20 )aryl) 2 , P(═O)(OH)(OM), P(═O)(OM) 2 , P═O(O 2 M), S(═O)(OH) 2 , S(═O)(O(C 1 -C 18 )alkylene(C 6 -C 20 )aryl) 2 , S(═O)(OH)(OM), S(═O)(OM) 2 ; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C 6 -C 20 )aryl, (C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkyl(C 6 -C 20 )aryl, (C 1 -C 18 )alkyl(C 6 -C 20 )heteroaryl, hydroxy(C 6 -C 20 )aryl, hydroxy(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkoxy(C 6 -C 20 )aryl, (C 1 -C 18 )alkoxy(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkylenedioxy(C 6 -C 20 )aryl, (C 1 -C 18 )alkylenedioxy(C 6 -C 20 )heteroaryl, halo(C 6 -C 20 )aryl, halo(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkylamino(C 6 -C 20 )aryl, (C 1 -C 18 )alkylamino(C 6 -C 20 )heteroaryl, (C 1 -C 18 )cycloalkylamino(C 6 -C 20 )aryl, or (C 1 -C 18 )cycloalkylamino(C 6 -C 20 )heteroaryl, and their OR 8 substutes; R 5 is (C 1 -C 18 alkoxy, hydrogen, hydroxyl, O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl, halo or OR 8 , or R 5 and R 6 are (C 1 -C 18 )dioxy provided that R 7 is hydrogen; R 6 is hydroxyl, O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl, halo or OR R , (C 1 -C 18 )alkoxy, (C 1 -C 18 )alkylamino, or (C 1 -C 18 )cycloalkylamino, or R 6 and R 7 are (C 1 -C 18 )dioxy provided that R 5 is hydrogen; R 7 is hydrogen, halo or OR 8 , hydroxyl, or O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl; and R 8 is P(═O)(OH) 2 , P(═O)(O(C 1 -C 18 )alkyl(C 6 -C 20 )aryl) 2 , P(═O)(OH)(OM), or P(═O)(OM) 2 , P═O(O 2 M).

  根据以下公式披露了一种化合物：或其药学上可接受的盐、前药、溶剂合物或代谢物，其中R为氢、P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、P(═O)(OM)2、P═O(O2M)、S(═O)(OH)2、S(═O)(O(C1-C18)烷基(C6-C20)芳基)2、S(═O)(OH)(OM)、S(═O)(OM)2；M为一价或二价金属离子，或烷基铵离子；W为(C6-C20)芳基、(C6-C20)杂芳基、(C1-C18)烷基(C6-C20)芳基、(C1-C18)烷基(C6-C20)杂芳基、羟基(C6-C20)芳基、羟基(C6-C20)杂芳基、(C1-C18)烷氧基(C6-C20)芳基、(C1-C18)烷氧基(C6-C20)杂芳基、(C1-C18)烷二氧基(C6-C20)芳基、(C1-C18)烷二氧基(C6-C20)杂芳基、卤代(C6-C20)芳基、卤代(C6-C20)杂芳基、(C1-C18)烷基氨基(C6-C20)芳基、(C1-C18)烷基氨基(C6-C20)杂芳基、(C1-C18)环烷基氨基(C6-C20)芳基，或(C1-C18)环烷基氨基(C6-C20)杂芳基，以及它们的OR8取代基；R5为(C1-C18)烷氧基、氢、羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或OR8，或R5和R6为(C1-C18)二氧基，前提是R7为氢；R6为羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或ORR、(C1-C18)烷氧基、(C1-C18)烷基氨基，或(C1-C18)环烷基氨基，或R6和R7为(C1-C18)二氧基，前提是R5为氢；R7为氢、卤素或OR8、羟基，或O—(C1-C18)烷基(C6-C20)芳基；R8为P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、或P(═O)(OM)2、P═O(O2M)。
• [EN] SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES<br/>[FR] SYNTHÈSE ET ACTIVITÉ ANTICANCÉREUSE DE DÉRIVÉS D'ARYL- ET D'HÉTÉROARYL-QUINOLÉINE
  申请人：EFFICIENT PHARMA MAN CORP

  公开号：WO2012009519A1

  公开（公告）日：2012-01-19

  A class of compounds that are derivatives and analogues of aryl and heteroaryl-quinolin is disclosed. Also disclosed are synthesis and use of the aryl and heteroaryl -quinolin derivatives and analogues for anticancer activities.

  本文披露了一类衍生自芳基和杂环芳基喹啉的化合物及其类似物。本文还披露了合成和使用这些芳基和杂环芳基喹啉衍生物和类似物进行抗癌活性的方法。
• Antitumor Agents 155. Synthesis and Biological Evaluation of 3',6,7-Substituted 2-Phenyl-4-quinolones as Antimicrotubule Agents
  作者：Leping Li、Hui-Kang Wang、Sheng-Chu Kuo、Tian-Shung Wu、Anthony Mauger、Chii M. Lin、Ernest Hamel、Kuo-Hsiung Lee

  DOI：10.1021/jm00046a025

  日期：1994.9

  A series of 3',6,7-substituted 2-phenyl-4-quinolones were designed and synthesized as antimitotic antitumor agents. All compounds showed cytotoxic effects (log GI(50) less than or equal to -4.0; log drug molar concentration required to cause 50% inhibition) against the growth of a variety of human tumor cell lines, including those derived from solid tumors such as non-small cell lung, colon, central nervous system, ovary, prostate, and breast cancers, when evaluated in the National Cancer Institute's 60 human tumor cell line in vitro screen. The most potent compound (26) demonstrated strong cytotoxic effects with GI(50) values in the nanomolar or subnanomolar range in almost all the tumor cell lines. Compound 26 was also a potent inhibitor of tubulin polymerization and radiolabeled colchicine binding to tubulin, with activity comparable to those of the potent antimitotic natural products colchicine, podophyllotoxin, and combretastatin A-4.
• Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead
  作者：Yung-Yi Cheng、Chin-Yu Liu、Meng-Tung Tsai、Hui-Yi Lin、Jai-Sing Yang、Tian-Shung Wu、Sheng-Chu Kuo、Li-Jiau Huang、Kuo-Hsiung Lee

  DOI：10.1016/j.bmcl.2013.06.083

  日期：2013.9

  New 6- (or 6,7-) substituted 2-(hydroxyl substituted phenyl)quinolin-4-one derivatives were synthesized and screened for antiproliferative effects against cancer cell lines. Structure-activity relationship correlations were established and the most promising compound 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidin-1-ylquinolin-4-one (6h) exhibited strong inhibitory activity against various human cancer cell lines, particularly non-small cell lung cancer NCI-H522. Additional studies suggested a mechanism of action resembling that of the antimitotic drug vincristine. The presence of a C-ring OH group in 6h will allow this compound to be converted readily to a water soluble and physicochemically stable hydrophilic prodrug. Compound 6h is proposed as a new anticancer lead compound. (C) 2013 Elsevier Ltd. All rights reserved.
• Design and synthesis of 2-(3-alkylaminophenyl)-6-(pyrrolidin-1-yl)quinolin-4-ones as potent antitumor agents
  作者：Shih-Ming Huang、Yung-Yi Cheng、Ming-Hua Chen、Chi-Hung Huang、Li-Jiau Huang、Mei-Hua Hsu、Sheng-Chu Kuo、Kuo-Hsiung Lee

  DOI：10.1016/j.bmcl.2012.11.105

  日期：2013.2

  2-(3-Alkylaminophenyl)-6-(pyrrolidin-1-yl)quinolin-4-ones 1-3 were synthesized and screened for anti-proliferative activity against three human cancer cell lines, as well as the normal cell line Detroit 551. All of the synthesized target compounds 1-3 demonstrated potent cytotoxic activity against the cancer cell lines, but weak inhibitory activity toward the normal cell line. 2-(3-Methyl aminophenyl)-6-(pyrrolidin-1-yl)quinolin-4-one (1), one of the potent compounds in vitro, was also tested in an in vivo Hep3B xenograft nude mice model, and its significant anticancer activity was reconfirmed. Therefore, compound 1 merits further investigation as an antitumor clinical trial candidate and potential anticancer agent. (c) 2012 Elsevier Ltd. All rights reserved.